Extract of Mangifera indica L. (Vimang®)- Third age- Phase II.

Phase 2

Conditions: Aging
Growth and Development
Physiological Processes
Physiological Phenomena

Registration Number: RPCEC00000003

Lead Sponsor: Center of Pharmaceutical Chemistry

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 64

Inclusion Criteria

1. Persons with 60 year-old or more 2. Written acceptance and voluntary of participating in the clinical trial 3. Good psychological conditions. 4. People that are internal in the Home. 5. Both sexes.

Exclusion Criteria

1. Infection systemic chronicle. 2. Treatment with anti oxidanting in the last month. 3. Current Hyperbaric Oxygenation or in one period of up to 15 days before the moment of their inclusion. 4. Immunosupresive Therapy or steroids therapy in the moment of their inclusion or in the last 3 months. 5. Renal chronicle or failure or hepatical demonstrated clinically. 6. People with cognitive damage. 7. People with dysphagia. 8. People in period of convalescence (up to two weeks) of a sharp infectious illness that could alter the immune answer. 9. Hypersensibility reaction to the components of the formulation.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anti oxidating total (AOT). This variable will be measured to the beginning, 3 months of initiate the treatment and to the 6 months.

Secondary Outcome Measures

Name	Time	Method
Potential peroxidation, reduced, total and oxidated Glutation. Oxidated proteins. Lipid Lipoperoxidation . Catalasa. Dismutasa superoxide, Glutation S - transferasa. Glutation reductasa, Total Hydroperoxides, indicators of quality of life, Filtered glomerular. These variables will be measured to the beginning, 3 months of initiate the treatment and to the 6 months.